Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Autonomous & Electric Vehicles (DRIV) vs Smith & Nephew plc (SNN) Price & Performance

Global X Autonomous & Electric VehiclesTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Global X Autonomous & Electric Vehicles vs Smith & Nephew plc — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.79 (market cap $356.37M), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 31.1× Global X Autonomous & Electric Vehicles's market cap, and Smith & Nephew plc pays a 2.95% dividend while Global X Autonomous & Electric Vehicles pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 40 Days and Smith & Nephew plc for 121 Days on average.

DRIVSNN
Market Cap
$356.37M$11.10B
Volume
22,3971,051,703
Sector
Sector/ThematicHealth
52-Week High
$42.53$37.17
52-Week Low
$27.58$26.42
Typical Hold Time
40 Days121 Days
Enterprise Value
—$14.13B
Dividend Yield
—2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Autonomous & Electric Vehicles

DRIV trades at $32.60, down 2.29% today amid mixed technical signals with a bullish overall signal but bearish moving averages. The stock shows neutral momentum oscillators with RSI at 51.36 indicating balanced buying and selling pressure. Recent automotive sector news highlights hybrid vehicle momentum and China's ambitious EV targets, potentially benefiting automotive-focused ETFs.

The stock faces near-term resistance at $34 with technical indicators suggesting consolidation. Automotive sector transformation creates both opportunities from EV/hybrid adoption and risks from oil price volatility. Market sentiment remains divided as investors weigh technological shifts against traditional automotive challenges.

Smith & Nephew plc

SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.

The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.

Returns comparison

Trailing returns across standard periods

About Global X Autonomous & Electric Vehicles

DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.

Read more on DRIV →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →